Robert J Adelman Net Worth

The estimated Net Worth of Robert J Adelman is at least $114 Tausend dollars as of 18 September 2020. Robert Adelman owns over 230,000 units of Metacrine stock worth over $113,827 and over the last 4 years Robert sold MTCR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Robert Adelman MTCR stock SEC Form 4 insiders trading

Robert has made over 1 trades of the Metacrine stock since 2020, according to the Form 4 filled with the SEC. Most recently Robert bought 230,000 units of MTCR stock worth $2,990,000 on 18 September 2020.

The largest trade Robert's ever made was buying 230,000 units of Metacrine stock on 18 September 2020 worth over $2,990,000. On average, Robert trades about 230,000 units every 0 days since 2020. As of 18 September 2020 Robert still owns at least 230,000 units of Metacrine stock.

You can see the complete history of Robert Adelman stock trades at the bottom of the page.

What's Robert Adelman's mailing address?

Robert's mailing address filed with the SEC is C/O METACRINE, INC., 3985 SORRENTO VALLEY BLVD., SUITE C, SAN FRANCISCO, CA, 92121.

Insiders trading at Metacrine

Over the last 4 years, insiders at Metacrine have traded over $5,582,700 worth of Metacrine stock and bought 11,645,167 units worth $119,461,162 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Metacrine executives and independent directors trade stock every 24 days with the average trade being worth of $237,397. The most recent stock trade was executed by Michael York on 26 January 2023, trading 107,054 units of MTCR stock currently worth $43,892.

What does Metacrine do?

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Complete history of Robert Adelman stock trades at Metacrine

Metacrine executives and stock owners

Metacrine executives and other stock owners filed with the SEC include:

• Dr. Preston S. Klassen M.D., M.H.S.,
  Pres, CEO & Director
• Dr. Preston S. Klassen,
  Pres, CEO & Director
• Patricia M. Millican,
  Chief Financial Officer
• Catherine C. Lee,
  Consultant
• Michael B. York,
  Chief Bus. Officer
• Theresa Lowry,
  VP of HR
• Patricia Millican,
  Chief Financial Officer
• Andrew Guggenhime,
  Director
• Jeffrey David Jonker,
  Director
• John G Mc Hutchison,
  Director
• Venture Fund Viii, L.P.Arch...,
  
• Kristina Burow,
  Director
• Preston Klassen,
  Director
• Enterprise Associates 16, L...,
  
• Trisha Millican,
  Chief Financial Officer
• Forest Baskett,
  10% owner
• Ali Behbahani,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Ronald M Evans,
  Director
• Carmen Chang,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Amir Nashat,
  Director
• Management Co. Vii, L.L.C.P...,
  
• Joshua Makower,
  10% owner
• Scott D Sandell,
  10% owner
• Peter W. Sonsini,
  10% owner
• Paul Edward Walker,
  10% owner
• Global Strategic Fund, L.P....,
  
• Robert J Adelman,
  
• Hubert C Chen,
  Chief Medical Officer
• Catherine Chai Zon Lee,
  EVP, Gen. Counsel & Secretary
• Julia C. Owens,
  Director
• Richard A. Heyman,
  Director
• Global Strategic Fund, L.P....,
  
• Michael York,
  Chief Business Officer
• Braden Michael Leonard,
  10% owner